{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:49:29Z","timestamp":1777502969936,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["TCR Flagship and Centre Grant NMRC\/TCR\/009-NUHS\/2013"],"award-info":[{"award-number":["TCR Flagship and Centre Grant NMRC\/TCR\/009-NUHS\/2013"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4234-8","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T02:48:17Z","timestamp":1522810097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A phase I\/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Raghav","family":"Sundar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamaue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Katsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Song","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousaku","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ley-Fang","family":"Kua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Peng","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"key":"4234_CR1","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903\u20139.","journal-title":"J Clin Oncol"},{"key":"4234_CR2","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1002\/cncr.25064","volume":"116","author":"SE Al-Batran","year":"2010","unstructured":"Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010;116:2511\u20138.","journal-title":"Cancer"},{"key":"4234_CR3","doi-asserted-by":"publisher","unstructured":"Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010:Cd004064. https:\/\/doi.org\/10.1002\/14651858.CD004064.pub3 .","DOI":"10.1002\/14651858.CD004064.pub3"},{"key":"4234_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1476-4598-9-45","volume":"9","author":"MT Teh","year":"2010","unstructured":"Teh MT, Gemenetzidis E, Chaplin T, Young BD, Philpott MP. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer. 2010;9:45.","journal-title":"Mol Cancer"},{"key":"4234_CR5","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1038\/sj.onc.1210466","volume":"26","author":"M Kanehira","year":"2007","unstructured":"Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene. 2007;26:6448\u201355.","journal-title":"Oncogene"},{"key":"4234_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1158\/0008.5472.CAN-04-3646","volume":"65","author":"K Taniuchi","year":"2005","unstructured":"Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, et al. Down-regulation of RAB6KIFL\/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res. 2005;65:105\u201312.","journal-title":"Cancer Res"},{"key":"4234_CR7","doi-asserted-by":"publisher","first-page":"11601","DOI":"10.1158\/0008-5472.CAN-07-3243","volume":"67","author":"N Ishikawa","year":"2007","unstructured":"Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 2007;67:11601\u201311.","journal-title":"Cancer Res"},{"key":"4234_CR8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0002-9440(10)63711-X","volume":"164","author":"DM Roberts","year":"2004","unstructured":"Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol. 2004;164:1531\u20135.","journal-title":"Am J Pathol"},{"key":"4234_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1245\/s10434-007-9596-0","volume":"15","author":"E Lieto","year":"2008","unstructured":"Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15:69\u201379.","journal-title":"Ann Surg Oncol"},{"key":"4234_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/j.1349-7006.2007.00603.x","volume":"98","author":"T Suda","year":"2007","unstructured":"Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007;98:1803\u20138.","journal-title":"Cancer Sci"},{"key":"4234_CR11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/j.1349-7006.2009.01200.x","volume":"100","author":"K Kono","year":"2009","unstructured":"Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009;100:1502\u20139.","journal-title":"Cancer Sci"},{"key":"4234_CR12","doi-asserted-by":"publisher","first-page":"848042","DOI":"10.1155\/2012\/848042","volume":"2012","author":"R Osawa","year":"2012","unstructured":"Osawa R, Tsunoda T, Yoshimura S, Watanabe T, Miyazawa M, Tani M, et al. Identification of HLA-A24-restricted novel T cell epitope peptides derived from P-cadherin and kinesin family member 20A. J Biomed Biotechnol. 2012;2012:848042.","journal-title":"J Biomed Biotechnol"},{"key":"4234_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/cas.12503","volume":"105","author":"K Mimura","year":"2014","unstructured":"Mimura K, Kua LF, Shiraishi K, Kee Siang L, Shabbir A, Komachi M, et al. Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-gamma treatment. Cancer Sci. 2014;105:1236\u201344.","journal-title":"Cancer Sci"},{"key":"4234_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"4234_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310.","journal-title":"Immunity"},{"key":"4234_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298\u2013306.","journal-title":"Nat Rev Cancer"},{"key":"4234_CR17","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/sj.bjc.6604738","volume":"99","author":"HE Lee","year":"2008","unstructured":"Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99:1704\u201311.","journal-title":"Br J Cancer"},{"key":"4234_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1136\/gutjnl-2014-308252","volume":"64","author":"SJ Lin","year":"2015","unstructured":"Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015;64:1721\u201331.","journal-title":"Gut"},{"key":"4234_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","volume":"39","author":"J Galon","year":"2013","unstructured":"Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39:11\u201326.","journal-title":"Immunity"},{"key":"4234_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2015.11.009","volume":"39","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Dieu-Nosjean MC, Sautes-Fridman C, Fridman WH. Cancer immune contexture and immunotherapy. Curr Opin Immunol. 2016;39:7\u201313.","journal-title":"Curr Opin Immunol"},{"key":"4234_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"4234_CR22","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138.","journal-title":"J Clin Oncol"},{"key":"4234_CR23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3892\/ijo.2013.2242","volume":"44","author":"Y Higashihara","year":"2014","unstructured":"Higashihara Y, Kato J, Nagahara A, Izumi K, Konishi M, Kodani T, et al. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol. 2014;44:662\u20138.","journal-title":"Int J Oncol"},{"key":"4234_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10120-013-0258-6","volume":"17","author":"H Ishikawa","year":"2014","unstructured":"Ishikawa H, Imano M, Shiraishi O, Yasuda A, Peng YF, Shinkai M, et al. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric Cancer. 2014;17:173\u201380.","journal-title":"Gastric Cancer"},{"key":"4234_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3892\/ijo.2012.1573","volume":"41","author":"T Masuzawa","year":"2012","unstructured":"Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, et al. Phase I\/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41:1297\u2013304.","journal-title":"Int J Oncol"},{"key":"4234_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clim.2016.03.015","volume":"166-167","author":"M Murahashi","year":"2016","unstructured":"Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H, et al. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016;166-167:48\u201358.","journal-title":"Clin Immunol"},{"key":"4234_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1349-7006.2009.01416.x","volume":"101","author":"M Miyazawa","year":"2010","unstructured":"Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010;101:433\u20139.","journal-title":"Cancer Sci"},{"key":"4234_CR28","first-page":"3950","volume":"7","author":"Y Miyagi","year":"2001","unstructured":"Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res. 2001;7:3950\u201362.","journal-title":"Clin Cancer Res"},{"key":"4234_CR29","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00262-009-0695-6","volume":"58","author":"T Hattori","year":"2009","unstructured":"Hattori T, Mine T, Komatsu N, Yamada A, Itoh K, Shiozaki H, et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother. 2009;58:1843\u201352.","journal-title":"Cancer Immunol Immunother"},{"key":"4234_CR30","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3892\/ijo.2017.3955","volume":"50","author":"Y Fujiwara","year":"2017","unstructured":"Fujiwara Y, Okada K, Omori T, Sugimura K, Miyata H, Ohue M, et al. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017;50:1655\u201362.","journal-title":"Int J Oncol"},{"key":"4234_CR31","doi-asserted-by":"crossref","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;390(10111):2461\u201371.","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"4234_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717\u201326.","journal-title":"Lancet Oncol"},{"key":"4234_CR33","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19:1597\u2013608.","journal-title":"Nat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4234-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4234-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4234-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T18:18:24Z","timestamp":1720203504000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4234-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4234"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4234-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]},"assertion":[{"value":"27 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization guideline on Good Clinical Practice, and applicable local regulatory requirements and laws. All patients provided written informed consent before any study-specific activities were performed. Investigators obtained prospective approval of the study protocol, protocol amendments, informed consent forms, and other relevant documents from the Institutional Review Board\/Independent Ethics Committee, National Healthcare Group Domain Specific Review Board Ref No: 2010\/00575.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as individual patient data is not being published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HY has received a research grant from Oncotherapy Science. YWP has received a research grant from Oncotherapy Science. None of the other authors have any conflict of interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"332"}}